Skip to main content
NCBI home page
Infection and Immunity logoLink to Infection and Immunity
. 1988 Nov;56(11):2769–2773. doi: 10.1128/iai.56.11.2769-2773.1988

Immunization against tuberculosis: what kind of vaccine?

A J Crowle 1
PMCID: PMC259648  PMID: 3049373

Full text

PDF
2769

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. BAER H., CHAPARAS S. D. TUBERCULIN REACTIVITY OF A CARBOHYDRATE COMPONENT OF UNHEATED BCG CULTURE FILTRATE. Science. 1964 Oct 9;146(3641):245–247. doi: 10.1126/science.146.3641.245. [DOI] [PubMed] [Google Scholar]
  2. CROWLE A. J. Immunizing constituents of the tubercle bacillus. Bacteriol Rev. 1958 Sep;22(3):183–203. doi: 10.1128/br.22.3.183-203.1958. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. CROWLE A. J. Tubercle bacillary extracts immunogenic for mice. 1. Factors affecting demonstration of their activity. Tubercle. 1961 Dec;42:470–478. doi: 10.1016/s0041-3879(61)80136-0. [DOI] [PubMed] [Google Scholar]
  4. CROWLE A. J. Tubercle bacillary extracts immunogenic for mice. 3. Chemical degradation studies on the immunogen extracted from tubercle bacilli by trypsin digestion. Tubercle. 1962 Jun;43:178–184. doi: 10.1016/s0041-3879(62)80038-5. [DOI] [PubMed] [Google Scholar]
  5. CROWLE A. J. Tubercle bacillary extracts immunogenic for mice. 4. Lipids. Proc Soc Exp Biol Med. 1962 Apr;109:969–971. doi: 10.3181/00379727-109-27393. [DOI] [PubMed] [Google Scholar]
  6. Chaparas S. D. The immunology of mycobacterial infections. Crit Rev Microbiol. 1982;9(2):139–197. doi: 10.3109/10408418209104488. [DOI] [PubMed] [Google Scholar]
  7. Chaparas S. D., Thor D. E., Godfrey H. P., Baer H., Hedrick S. R. Tuberculin-active carbohydrate that induces inhibition of macrophage migration but not lymphocyte transformation. Science. 1970 Nov 6;170(3958):637–639. doi: 10.1126/science.170.3958.637. [DOI] [PubMed] [Google Scholar]
  8. Colley D. G. Intradermal immune responses to a schistosomal egg antigen during experimental murine Schistosoma mansoni infection. Proc Soc Exp Biol Med. 1972 Jul;140(3):772–775. doi: 10.3181/00379727-140-36550. [DOI] [PubMed] [Google Scholar]
  9. Collins F. M., Lamb J. R., Young D. B. Biological activity of protein antigens isolated from Mycobacterium tuberculosis culture filtrate. Infect Immun. 1988 May;56(5):1260–1266. doi: 10.1128/iai.56.5.1260-1266.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Crowle A. J., Hu C. C. Delayed hypersensitivity in mice to dextran. Int Arch Allergy Appl Immunol. 1967;31(2):123–144. doi: 10.1159/000229861. [DOI] [PubMed] [Google Scholar]
  11. Crowle A. J., Jarrett K. Importance of phosphate in Freund adjuvant. Proc Soc Exp Biol Med. 1972 May;140(1):304–306. doi: 10.3181/00379727-140-36445. [DOI] [PubMed] [Google Scholar]
  12. Crowle A. J., May M. Preliminary demonstration of human tuberculoimmunity in vitro. Infect Immun. 1981 Jan;31(1):453–464. doi: 10.1128/iai.31.1.453-464.1981. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Crowle A. J., Patrucco A. Preferential development by mice of delayed hypersensitivity to purified basic proteins. J Allergy. 1968 Sep;42(3):140–156. doi: 10.1016/0021-8707(68)90087-7. [DOI] [PubMed] [Google Scholar]
  14. Crowle A. J., Ross E. J., May M. H. Inhibition by 1,25(OH)2-vitamin D3 of the multiplication of virulent tubercle bacilli in cultured human macrophages. Infect Immun. 1987 Dec;55(12):2945–2950. doi: 10.1128/iai.55.12.2945-2950.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Daniel T. M., Janicki B. W. Mycobacterial antigens: a review of their isolation, chemistry, and immunological properties. Microbiol Rev. 1978 Mar;42(1):84–113. doi: 10.1128/mr.42.1.84-113.1978. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Douvas G. S., Berger E. M., Repine J. E., Crowle A. J. Natural mycobacteriostatic activity in human monocyte-derived adherent cells. Am Rev Respir Dis. 1986 Jul;134(1):44–48. doi: 10.1164/arrd.1986.134.1.44. [DOI] [PubMed] [Google Scholar]
  17. Douvas G. S., Looker D. L., Vatter A. E., Crowle A. J. Gamma interferon activates human macrophages to become tumoricidal and leishmanicidal but enhances replication of macrophage-associated mycobacteria. Infect Immun. 1985 Oct;50(1):1–8. doi: 10.1128/iai.50.1.1-8.1985. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Farer L. S. Tuberculosis--a continuing problem. Am Rev Respir Dis. 1986 Jul;134(1):2–3. doi: 10.1164/arrd.1986.134.1.2. [DOI] [PubMed] [Google Scholar]
  19. Flesch I., Kaufmann S. H. Mycobacterial growth inhibition by interferon-gamma-activated bone marrow macrophages and differential susceptibility among strains of Mycobacterium tuberculosis. J Immunol. 1987 Jun 15;138(12):4408–4413. [PubMed] [Google Scholar]
  20. Fujiwara T., Hunter S. W., Cho S. N., Aspinall G. O., Brennan P. J. Chemical synthesis and serology of disaccharides and trisaccharides of phenolic glycolipid antigens from the leprosy bacillus and preparation of a disaccharide protein conjugate for serodiagnosis of leprosy. Infect Immun. 1984 Jan;43(1):245–252. doi: 10.1128/iai.43.1.245-252.1984. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Grange J. M. Molecular biology: new hopes and challenges. Tubercle. 1988 Mar;69(1):1–4. doi: 10.1016/0041-3879(88)90034-7. [DOI] [PubMed] [Google Scholar]
  22. Haegi V. Tuberkulosepsis bei HIV-Infektion. Schweiz Med Wochenschr. 1987 Aug 29;117(35):1297–1301. [PubMed] [Google Scholar]
  23. Hahn H., Kaufmann S. H. The role of cell-mediated immunity in bacterial infections. Rev Infect Dis. 1981 Nov-Dec;3(6):1221–1250. doi: 10.1093/clinids/3.6.1221. [DOI] [PubMed] [Google Scholar]
  24. Hart P. D. Biology of the mycobacterioses. Statement of questions. Ann N Y Acad Sci. 1968 Sep 5;154(1):3–7. doi: 10.1111/j.1749-6632.1968.tb16689.x. [DOI] [PubMed] [Google Scholar]
  25. Kaufmann S. Towards new leprosy and tuberculosis vaccines. Microbiol Sci. 1987 Nov;4(11):324–328. [PubMed] [Google Scholar]
  26. Khuller G. K., Malik U., Subrahmanyam D. Immunological studies with sulpholipids of mycobacteria. Tubercle. 1982 Jun;63(2):107–111. doi: 10.1016/s0041-3879(82)80046-9. [DOI] [PubMed] [Google Scholar]
  27. LEON A. P., GIL M., DE ITA G. [Attempts at artificial immunization agaist tuberculosis with synthetic antigens]. Rev Inst Salubr Enferm Trop. 1961 Dec;21:155–192. [PubMed] [Google Scholar]
  28. Lederer E. Structure de constituants mycobactériens: relation avec l'activité immunologique. Ann Microbiol (Paris) 1978 Jan;129(1):91–93. [PubMed] [Google Scholar]
  29. León A. P. Research on artificial immunization against tuberculosis with synthetic antigens. II. Immunization of white mice and guinea pigs with Pogal. Dis Chest. 1967 Oct;52(4):495–504. doi: 10.1378/chest.52.4.495. [DOI] [PubMed] [Google Scholar]
  30. León A. P. Ulteriores ensayos de inmunización artificial contral la tuberculosis con antígenos sinteticos. II. Inmunización de ratones blancos y cobayos con POGAL. Rev Inst Salubr Enferm Trop. 1965 Jan-Jun;25(1):61–81. [PubMed] [Google Scholar]
  31. Lu M. C., Lien M. H., Becker R. E., Heine H. C., Buggs A. M., Lipovsek D., Gupta R., Robbins P. W., Grosskinsky C. M., Hubbard S. C. Genes for immunodominant protein antigens are highly homologous in Mycobacterium tuberculosis, Mycobacterium africanum, and the vaccine strain Mycobacterium bovis BCG. Infect Immun. 1987 Oct;55(10):2378–2382. doi: 10.1128/iai.55.10.2378-2382.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Mycobacterioses and the acquired immunodeficiency syndrome. Joint Position Paper of the American Thoracic Society and the Centers for Disease Control. Am Rev Respir Dis. 1987 Aug;136(2):492–496. doi: 10.1164/ajrccm/136.2.492. [DOI] [PubMed] [Google Scholar]
  33. OPRESCU C. C. [On the presence of a "protector antigen" in tubercle bacilli]. Rev Immunol Ther Antimicrob. 1961 Jul-Sep;25:278–291. [PubMed] [Google Scholar]
  34. Oprescu C. C. Present status of the antituberculous immunity. J Hyg Epidemiol Microbiol Immunol. 1975;19(4):400–406. [PubMed] [Google Scholar]
  35. Orme I. M. Characteristics and specificity of acquired immunologic memory to Mycobacterium tuberculosis infection. J Immunol. 1988 May 15;140(10):3589–3593. [PubMed] [Google Scholar]
  36. Ortiz-Ortiz L., Bojalil L. F., Contreras M. F. Delayed hypersensitivity to polysaccharides from nocardia. J Immunol. 1972 May;108(5):1409–1413. [PubMed] [Google Scholar]
  37. Portelance V., Beaudet R. Biochemical characterization of three mycobacterial ribosomal fractions. Can J Microbiol. 1983 Feb;29(2):185–193. doi: 10.1139/m83-032. [DOI] [PubMed] [Google Scholar]
  38. Portelance V., Boulanger R. P., Brasseur R. Induction of antituberculous immunity by polysaccharidic contaminants of crude ribosomal vaccines isolated from Mycobacterium bovis, strain BCG. Rev Can Biol. 1977 Sep;36(3):265–275. [PubMed] [Google Scholar]
  39. Portelance V., Brasseur R., Boulanger R. P. Factors affecting the immunizing activity of ribosomal fractions isolated from Mycobacterium tuberculosis var. bovis strain BCG. Can J Microbiol. 1975 Oct;21(10):1492–1499. doi: 10.1139/m75-221. [DOI] [PubMed] [Google Scholar]
  40. Prignot J., Sonnet J. AIDS, tuberculosis and mycobacterioses. Bull Int Union Tuberc Lung Dis. 1987 Dec;62(4):7–10. [PubMed] [Google Scholar]
  41. RAFFEL S. The J. Burns Amberson lecture: aspects of contemporary research in immunology. Am Rev Respir Dis. 1960 Oct;82:461–468. doi: 10.1164/arrd.1960.82.4.461. [DOI] [PubMed] [Google Scholar]
  42. Reggiardo Z., Middlebrook G. Delayed-type hypersensitivity and immunity against aerogenic tuberculosis in guinea pigs. Infect Immun. 1974 May;9(5):815–820. doi: 10.1128/iai.9.5.815-820.1974. [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Ribi E., Anacker R. L., Barclay W. R., Brehmer W., Middlebrook G., Milner K. C., Tarmina D. F. Biology of the mycobacterioses. Structure and biological functions of mycobacteria. Ann N Y Acad Sci. 1968 Sep 5;154(1):41–57. doi: 10.1111/j.1749-6632.1968.tb16694.x. [DOI] [PubMed] [Google Scholar]
  44. Rook G. A. Progress in the immunology of the mycobacterioses. Clin Exp Immunol. 1987 Jul;69(1):1–9. [PMC free article] [PubMed] [Google Scholar]
  45. Rook G. A., Steele J., Fraher L., Barker S., Karmali R., O'Riordan J., Stanford J. Vitamin D3, gamma interferon, and control of proliferation of Mycobacterium tuberculosis by human monocytes. Immunology. 1986 Jan;57(1):159–163. [PMC free article] [PubMed] [Google Scholar]
  46. Rook G. A., Taverne J., Leveton C., Steele J. The role of gamma-interferon, vitamin D3 metabolites and tumour necrosis factor in the pathogenesis of tuberculosis. Immunology. 1987 Oct;62(2):229–234. [PMC free article] [PubMed] [Google Scholar]
  47. Sadoff J. C., Ballou W. R., Baron L. S., Majarian W. R., Brey R. N., Hockmeyer W. T., Young J. F., Cryz S. J., Ou J., Lowell G. H. Oral Salmonella typhimurium vaccine expressing circumsporozoite protein protects against malaria. Science. 1988 Apr 15;240(4850):336–338. doi: 10.1126/science.3281260. [DOI] [PubMed] [Google Scholar]
  48. Smith D. W., Grover A. A., Wiegeshaus E. Nonliving immunogenic substances of Mycobacteria. Bibl Tuberc. 1968;24:191–227. [PubMed] [Google Scholar]
  49. Stewart-Tull D. E. The immunological activities of bacterial peptidoglycans. Annu Rev Microbiol. 1980;34:311–340. doi: 10.1146/annurev.mi.34.100180.001523. [DOI] [PubMed] [Google Scholar]
  50. Suzuki M., Hayashi Y. Skin reaction and macrophage migration inhibition tests for polysaccharides from Aspergillus fumigatus and Candida albicans. Jpn J Microbiol. 1975 Oct;19(5):355–362. doi: 10.1111/j.1348-0421.1975.tb00892.x. [DOI] [PubMed] [Google Scholar]
  51. Uyeki E. M., Klassen R. S., Llacer V. Analysis of dextran- and methylated albumin-induced hypersensitivity by mouse paw swelling. Proc Soc Exp Biol Med. 1969 Dec;132(3):1140–1146. doi: 10.3181/00379727-132-34383. [DOI] [PubMed] [Google Scholar]
  52. WEISS D. W. Vaccination against tuberculosis with nonliving vaccines. I. The problem and its historical background. Am Rev Respir Dis. 1959 Sep;80:340–358. doi: 10.1164/arrd.1959.80.3.340. [DOI] [PubMed] [Google Scholar]
  53. Woolcock A. J. L'immunologie des maladies respiratoires non tuberculeuses: rôle des réactions d'hypersensibilité immédiate. Bull Int Union Tuberc. 1983 Mar;58(1):72–75. [PubMed] [Google Scholar]
  54. Yamamura Y., Maeda H., Ogawa Y., Hashimoto T. Experimental pulmonary cavity formation by mycobacterial components and synthetic adjuvants. Microbiol Immunol. 1986;30(11):1175–1187. doi: 10.1111/j.1348-0421.1986.tb03046.x. [DOI] [PubMed] [Google Scholar]
  55. Yamamura Y., Ogawa Y., Maeda H., Yamamura Y. Prevention of tuberculous cavity formation by desensitization with tuberculin-active peptide. Am Rev Respir Dis. 1974 Jun;109(6):594–601. doi: 10.1164/arrd.1974.109.6.594. [DOI] [PubMed] [Google Scholar]
  56. ten Dam H. G. Research on BCG vaccination. Adv Tuberc Res. 1984;21:79–106. [PubMed] [Google Scholar]

Articles from Infection and Immunity are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES